QScreen AI Advances Structured Commercial Discussions Following Canadian Trade Mission to Mexico

Rhea-AI Summary

QScreen AI (OTC: PMEDF) reported substantive commercialization discussions during the Government of Canada trade mission to Mexico on February 23, 2026. The company held structured one-on-one meetings across healthcare, defense, advanced manufacturing, agri-food, infrastructure, and AI ecosystems.

Discussions advanced to defined follow-up talks to shape pilot scope, deployment parameters, and integration requirements; definitive agreements remain subject to customary commercial evaluation and approvals. The company noted a recent U.S. patent filing and said Mexico represents a sizable addressable opportunity for enterprise-scale Quantum-AI screening solutions.

Toronto, Ontario--(Newsfile Corp. - February 23, 2026) - QScreen AI Inc (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP), an innovator fusing Quantum-AI technologies to transform health screening and employee wellness, today provided an update on its participation in the official Government of Canada Trade Mission to Mexico, reporting substantive commercialization discussions with senior institutional and enterprise stakeholders as part of its broader North American growth strategy.

Building on its recent U.S. patent filing and increased national visibility, QScreen AI leveraged its inclusion in the Canadian delegation to accelerate direct market engagement in Mexico, one of North America's largest and fastest-growing industrial and institutional economies.

During the mission, the Company conducted structured, one-on-one meetings across key sectors including:

• Public and institutional healthcare systems including defense
• Advanced manufacturing and industrial operations
• Agri-food and high-capacity processing groups
• Infrastructure and workforce-dense operational environments
• AI and technology innovation ecosystems

Discussions were centered on defined commercialization pathways, pilot program structuring, and integration of QScreen AI's platform into high-throughput operational settings. Multiple engagements have progressed to structured follow-up discussions focused on defining pilot scope, deployment parameters, and integration requirements within localized operational environments.

While definitive agreements remain subject to customary commercial processes, management believes the progression to senior-level, implementation-focused dialogue reflects meaningful commercial engagement and continued development of the Company's international pipeline.

Expanding Addressable Opportunity

Mexico's industrial base, workforce scale, and institutional modernization initiatives represent a sizable addressable opportunity for Quantum-AI-enabled technologies capable of operating at enterprise scale. The Company's engagements during the mission were concentrated with organizations managing large employee populations and complex compliance environments, sectors where scalable deployment can translate into recurring, multi-site implementation potential.

Dr. Rahul Kushwah, Co-Founder and Chief Scientific Officer, commented: "Our focus during the mission was disciplined commercialization. The dialogue moved quickly from introduction to practical implementation and pilot structuring. The level of engagement reinforces the applicability of our platform across multiple sectors and supports our strategy of building long-term commercial relationships in key North American markets."

QScreen AI is advancing structured follow-up discussions with select organizations to further define pilot scope, deployment parameters, and operational integration requirements. These engagements remain subject to customary commercial evaluation and internal approval processes. The Company continues to focus on disciplined execution and measured commercialization efforts across North America.

About Qscreen AI Inc.

QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP) is an emerging provider of rapid health screening and remote patient care solutions globally. The Company's Smarthealth AI stations are powered by a proprietary artificial intelligence (AI) and use multispectral cameras to analyze physiological data patterns and predict a variety of health issues including 19 physiological vital parameters, impairment by drugs or alcohol, fatigue, or various mental illnesses. QScreen AI's proprietary remote patient care platform empowers medical professionals with a suite of AI-powered tools to improve patient health outcomes.

Contact
Dr. Rahul Kushwah, COO
rahul@predictmedix.com
(647) 889 6916

Caution Regarding Forward-Looking Information:
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the Company, including risks related to COVID-19; risks related to the Company's shares, including price volatility due to events that may or may not be within such party's control; reliance on management; and the emergency of additional competitors in the industry.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law.

Disclaimer: The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time.

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/284795

FAQ

What commercial progress did QScreen AI (PMEDF) report from the February 23, 2026 Canada–Mexico trade mission?

QScreen AI reported structured, senior-level commercialization discussions and follow-up meetings to define pilots and deployment details. According to the company, engagements moved from introductions to implementation-focused dialogue across healthcare, defense, manufacturing, agri-food, infrastructure, and tech sectors.

Does QScreen AI (PMEDF) have binding contracts from the Mexico trade mission on February 23, 2026?

No binding contracts were announced; discussions advanced to structured follow-ups and pilot scoping. According to the company, definitive agreements remain subject to customary commercial evaluation and internal approvals before any binding commitments.

How is QScreen AI (PMEDF) positioning its technology in Mexico after the February 23, 2026 mission?

QScreen AI is targeting large-scale institutional and enterprise deployments, emphasizing pilot programs and integration in high-throughput settings. According to the company, focus sectors include public healthcare, defense, advanced manufacturing, agri-food, infrastructure, and AI ecosystems.

What steps did QScreen AI (PMEDF) say would follow the trade mission discussions on February 23, 2026?

The company said it will advance structured follow-up talks to define pilot scope, deployment parameters, and integration requirements. According to the company, these steps remain subject to customary commercial review and internal approval processes.

Did QScreen AI (PMEDF) cite any intellectual property developments alongside the February 23, 2026 Mexico engagements?

Yes, the company referenced a recent U.S. patent filing as part of its commercialization narrative. According to the company, the patent filing and increased visibility supported accelerated market engagement during the mission.